Glaukos Corporation (NYSE:GKOS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item5.02. Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain
Officers.
(c)On February6, 2017, Glaukos Corporation (the Company)
announced that Joseph E. Gilliam has been appointed as its Chief
Financial Officer and Senior Vice President, Corporate
Development, with an anticipated starting date in May2017 (Start
Date). Mr.Gilliam will replace the Companys current Chief
Financial Officer Richard Harrison, who is retiring later in 2017
and will step down as Chief Financial Officer in connection with
the Start Date, as previously announced in a Current Report on
Form8-K filed with the Securities and Exchange Commission on
July14, 2016.
Mr.Gilliam, age 41, most recently served as Managing Director of
Healthcare Investment Banking at JPMorgan Chase, a position he
held from 2013 to 2017. Prior to that, Mr.Gilliam held various
positions of increasing responsibility at JPMorgan Chase,
including serving as Executive Director from 2009 to 2013, and,
beginning in 2007, his work at the firm focused exclusively on
financing and advisory transactions in the biotechnology, medical
technology, life sciences and diagnostics industries. He was a
founding member of the Beacon Groups West Coast office, which was
acquired by Chase Manhattan and merged with JPMorgan in 2001.
Mr.Gilliam began his career in the audit services division of
PricewaterhouseCoopers in 1998.
Mr.Gilliam holds a bachelors degree in business from Kelly
Undergraduate School of Indiana University.
Mr.Gilliam has entered into an Offer Letter with the Company, a
copy of which is attached to this Current Report as Exhibit99.2
(the Offer Letter). Mr.Gilliams starting annual base salary will
be $360,000. He will be eligible for an annual target bonus of up
to 50% of his base salary, based upon achievement of certain
Company and personal performance objectives. Additionally,
subject to the approval of the Board of Directors of the Company,
Mr.Gilliam is entitled to receive an equity grant of 300,000
options to purchase stock of the Company, with an exercise price
equal to the closing market price on the Start Date, and 100,000
units of restricted stock of the Company, which amount is subject
to adjustment as set forth in the Offer Letter. Mr.Gilliam is
eligible to participate in the Companys benefit plans that are
available to executive officers of the Company generally. This
description of the terms of Mr.Gilliams employment is subject in
all respects to the terms of the Offer Letter.
Item 7.01 Regulation FD Disclosure.
The press release issued by the Company announcing his
appointment is attached to this Current Report on Form8-K as
Exhibit99.1.
A copy of the press release is furnished as Exhibit99.1 to this
Current Report on Form8-K. This information shall not be deemed
filed for purposes of Section18 of the Securities Exchange Act of
1934, as amended, and is not incorporated by reference into any
filing of the Company, whether made before or after the date
hereof, regardless of any general incorporation language in such
filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit Number |
|
Description |
|
99.1 |
Press release of Glaukos Corporation, dated February6, |
|
|
99.2 |
Joseph E. Gilliam Offer Letter dated February3, 2017. |
About Glaukos Corporation (NYSE:GKOS)
Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent, an MIGS device measuring approximately one millimeter long and approximately 0.33 millimeter wide. MIGS procedures involve the insertion of a micro-scale device from within the eye’s anterior chamber through a corneal incision. The Company’s micro-scale injectable therapies include pipeline products, such as the iStent Inject, the iStent Supra and iDose. The iStent Inject includes approximately two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is an implant that is designed to provide a sustained release of a prostaglandin drug to lower intraocular pressure in glaucoma patients. Glaukos Corporation (NYSE:GKOS) Recent Trading Information
Glaukos Corporation (NYSE:GKOS) closed its last trading session up +0.76 at 43.59 with 501,028 shares trading hands.